Saturday 17 October 2026
Export LSDIF’s income statement to Excel — free account
Lucy Scientific Discovery Inc.
LSDIF Healthcare Drug Manufacturers Specialty & Generic
Operating cash flow growth for three consecutive years.
0.00
0.00
NaN
Follow LSDIF
Lucy Scientific Discovery Inc. (LSDIF) P/E ratio
Lucy Scientific Discovery Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2023 | 0.0× | — |
| Jun 2023 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IMCC IM Cannabis Corp. compare | n/m |
| BTAIQ BioXcel Therapeutics, Inc. compare | n/m |
| SBFM Sunshine Biopharma, Inc. compare | n/m |
| LSDIF Lucy Scientific Discovery Inc. | n/m |
| PTPI Petros Pharmaceuticals, Inc. compare | n/m |
| PRFX PainReform Ltd. compare | n/m |
| SXTC China SXT Pharmaceuticals, Inc. compare | n/m |
| NEPTF Neptune Wellness Solutions Inc. compare | n/m |
| AKAN Akanda Corp. compare | — |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)